Intraperitoneal chemotherapy for ovarian cancer: A question of feasibility?

Drug Resistance Updates

Volumn 6, Issue 4, 2003, Pages 165-167

  Willemse, Pax H B ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PACLITAXEL;

ABDOMINAL PAIN; BONE MARROW TOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; HUMAN; MALAISE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0141743334     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00061-X     Document Type: Note

References (16)

1. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., Franklin, E.W., Clarke-Pearson, D.L., Malviya, V.K., DuBeshter, B., 1996. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955.
2. Dedrick, R.L., Flessner, M.F., 1997. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J. Natl. Cancer Inst. 89, 480-487.
3. De Jong, R.S., Willemse, P.H.B., Boonstra, H., de Vries, E.G.E., van der Graaf, W.T., Sleijfer, D.T., van der Zee, A.G., Mulder, N.H., 1995. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second line treatment in patients with small volume residual disease. Eur. J. Cancer 31, 709-713.
4. Hofstra, L.S., Bos, A.M., de Vries, E.G., van der Zee, A.G., Willemsen, A.T., Rosing, H., Beijnen, J.H., Mulder, N.H., Aalders, J.G., Willemse, P.H., 2002. Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol. Oncol. 85, 517-523.
5. Kirmani, S., Braly, P.S., McClay, E.F., Saltzstein, S.L., Plaxe, S.C., Kim, S., Cates, C., Howell, S.B., 1994. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol. 54, 338-344.
6. Los, G., Verdegaal, E., Mutsaers, P., McVie, J.G., 1991. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol. 28, 159-165.
7. Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., Wadler, S., Sickel, J., 2001. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001-1007.
8. Markman, M., Reichman, B., Hakes, T., Lewis, Jr., J.L., Jones, W., Rubin, S., Barakat, R., Curtin, J., Almadrones, L., Hoskins, W., 1992. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small volume residual ovarian cancer. J. Clin. Oncol. 10, 1479-1484.
9. Nanninga, A.G., Willemse, P.H., Boonstra, H., De Vries, E.G., 1992. Low complication rate during intraperitoneal therapy through a totally implanted peritoneal access port in patients with ovarian cancer. Int. J. Gynecol. Cancer 2, 107-110.
10. Ozols, R.F., Locker, G.Y., Doroshow, J.H., Grotzinger, K.R., Myers, C.E., Young, R.C., 1979. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian carcinoma. Cancer Res. 39, 3209-3214.
11. Piccart-Gebhart, M.J., Floquet, A., Sarfone, G., Willemse, P., Kobierska, A., Vergote, I., Giargea, L., Coens, C., Awada, A, Vermorken, J.B., for the EORTC-GCG, 2003. Intraperitoneal (IP) cisplatin (P) versus observation: 8-year results of an EORTC-GCG randomized phase III study in FIGO stages II B-C, III ovarian cancer (O.C.) patients (pts) with apathologically complete remission (PCR) after p-based intravenous chemotherapy (CT). In: Proceedings of the American Society of Clinical Oncology, vol. 22 (abstract no. 1792).
12. Polyzos, A., Tsavaris, N., Kosmas, C., Giannikos, L., Katsikas, M., Kalahanis, N., Karatzas, G., Christodoulou, K., Giannakopoulos, K., Stamatiadis, D., Katsilambros, N., 1999. A comparitive study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56, 291-296.
13. Rothenberg, M.L., Liu, P.Y., Braly, P.S., Wilczynski, S.P., Hannigan, E.V., Wadler, S., Stuart, G., Jiang, C., Markman, M., Alberts, D.S., 2003. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J. Clin. Oncol. 21, 1313-1319.
14. Van der Burg, M.E., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A.J., Nardi, M., Renard, J., Pecorelli, S., 1995. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 332, 629-634.
15. Willemse, P.H.B., de Vos, F.Y.F.L, Bos, A.M.E., de Vries, E.G.E., van der Zee, A.G.J., Beijnen, J.H., Rosing, H., Mourits, M.J.E., Hospers, G.A.P., 2003. Intraperitoneal topotecan with standard carboplatin and paclitaxel in ovarian cancer is feasible. In: Proceeding of the American Society of Clinical Oncology, vol. 22 (abstract no. 1866).
16. Zylberberg, B., Dormont, D., Antoine, M., 1996. First line immunochemotherapy with cisplatin based protocols by IP and intravenous routes in ovarian cancer: technique and results in 82 cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 66, 57-64.